Advertisement
Screener

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax

2.0 / 5 stars · 23/57 Roast Me

TEVA PHARMACEUTICAL INDUSTRIES LIMITED Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax of -$7.00 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-10-27.

Discontinued › Expense Statement › Income Tax

us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax · last filed 2021-10-27

  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2021-09-30 was -$7.00M.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2021-06-30 was -$7.00M.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2021-03-31 was -$7.00M.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2020-12-31 was -$11.00M, a 127.50% decline year-over-year.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2020 was -$57.00M.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2019 was -$84.00M.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2018 was -$115.00M, a 182.14% decline from fiscal 2017.
  • TEVA PHARMACEUTICAL INDUSTRIES LIMITED other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2017 was $140.00M, a 70.65% decline from fiscal 2016.
Period endOther Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 monthOther Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month as first filedOther Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 monthOther Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 month as first filedOther Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 monthOther Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 month as first filedOther Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 12 month
2021-09-30-$7.00M
10-Q · filed 2021-10-27
-$14.00M
derived: sum of 2 quarters · filed 2021-10-27
-$21.00M
10-Q · filed 2021-10-27
-$32.00M
derived: sum of 4 quarters · filed 2021-10-27
2021-06-30-$7.00M
10-Q · filed 2021-07-28
-$14.00M
10-Q · filed 2021-07-28
-$25.00M
derived: sum of 3 quarters · filed 2021-07-28
-$34.00M
derived: sum of 4 quarters · filed 2021-10-27
2021-03-31-$7.00M
10-Q · filed 2021-04-28
-$18.00M
derived: sum of 2 quarters · filed 2021-04-28
-$27.00M
derived: sum of 3 quarters · filed 2021-10-27
-$34.00M
derived: sum of 4 quarters · filed 2021-10-27
2020-12-31-$11.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10
-$20.00M
derived: sum of 2 quarters · filed 2021-10-27
-$27.00M
derived: sum of 3 quarters · filed 2021-10-27
-$57.00M
10-K · filed 2021-02-10
2020-09-30-$9.00M
10-Q · filed 2021-10-27
-$16.00M
derived: sum of 2 quarters · filed 2021-10-27
-$46.00M
10-Q · filed 2021-10-27
-$6.00M
derived: sum of 4 quarters · filed 2021-10-27
2020-06-30-$7.00M
10-Q · filed 2021-07-28
-$37.00M
10-Q · filed 2021-07-28
$3.00M
derived: sum of 3 quarters · filed 2021-07-28
-$84.00M
derived: sum of 4 quarters · filed 2021-07-28
2020-03-31-$30.00M
10-Q · filed 2021-04-28
$10.00M
derived: sum of 2 quarters · filed 2021-04-28
-$77.00M
derived: sum of 3 quarters · filed 2021-04-28
-$67.00M
derived: sum of 4 quarters · filed 2021-04-28
2019-12-31$40.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10
-$47.00M
derived: sum of 2 quarters · filed 2021-02-10
-$37.00M
derived: sum of 3 quarters · filed 2021-02-10
-$84.00M
10-K · filed 2021-02-10
2019-09-30-$87.00M
10-Q · filed 2020-11-05
-$77.00M
derived: sum of 2 quarters · filed 2020-11-05
-$124.00M
10-Q · filed 2020-11-05
-$164.00M
derived: sum of 4 quarters · filed 2021-02-10
2019-06-30$10.00M
10-Q · filed 2020-08-05
-$37.00M
10-Q · filed 2020-08-05
-$77.00M
derived: sum of 3 quarters · filed 2021-02-10
-$96.00M
derived: sum of 4 quarters · filed 2021-02-10
2019-03-31-$47.00M
10-Q · filed 2020-05-07
-$87.00M
derived: sum of 2 quarters · filed 2021-02-10
-$106.00M
derived: sum of 3 quarters · filed 2021-02-10
-$206.00M
derived: sum of 4 quarters · filed 2021-02-10
2018-12-31-$40.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-10
-$59.00M
derived: sum of 2 quarters · filed 2021-02-10
-$159.00M
derived: sum of 3 quarters · filed 2021-02-10
-$115.00M
10-K · filed 2021-02-10
2018-09-30-$19.00M
10-Q · filed 2019-11-07
-$119.00M
derived: sum of 2 quarters · filed 2019-11-07
-$75.00M
10-Q · filed 2019-11-07
-$53.00M
derived: sum of 4 quarters · filed 2020-02-21
2018-06-30-$100.00M
10-Q · filed 2019-08-07
-$56.00M
10-Q · filed 2019-08-07
-$34.00M
derived: sum of 3 quarters · filed 2020-02-21
$15.00M
derived: sum of 4 quarters · filed 2020-02-21
2018-03-31$44.00M
10-Q · filed 2019-05-02
$66.00M
derived: sum of 2 quarters · filed 2020-02-21
$115.00M
derived: sum of 3 quarters · filed 2020-02-21
$192.00M
derived: sum of 4 quarters · filed 2020-02-21
2017-12-31$22.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
$71.00M
derived: sum of 2 quarters · filed 2020-02-21
$148.00M
derived: sum of 3 quarters · filed 2020-02-21
$140.00M
10-K · filed 2020-02-21
2017-09-30$49.00M
10-Q · filed 2018-11-01
$126.00M
derived: sum of 2 quarters · filed 2018-11-01
$118.00M
10-Q · filed 2018-11-01
$85.00M
derived: sum of 4 quarters · filed 2018-11-01
2017-06-30$77.00M
10-Q · filed 2018-08-02
$69.00M
10-Q · filed 2018-08-02
$36.00M
derived: sum of 3 quarters · filed 2018-08-02
$25.00M
derived: sum of 4 quarters · filed 2018-08-02
2017-03-31-$8.00M
10-Q · filed 2018-05-03
-$41.00M
derived: sum of 2 quarters · filed 2018-05-03
-$52.00M
derived: sum of 3 quarters · filed 2018-05-03
$133.00M
derived: sum of 4 quarters · filed 2018-05-03
2016-12-31-$33.00M
derived: 10-K 12 month − 6-K 9 month · filed 2018-02-12
-$44.00M
derived: sum of 2 quarters · filed 2018-02-12
$141.00M
derived: sum of 3 quarters · filed 2018-02-12
$477.00M
10-K · filed 2019-02-19
2016-09-30-$11.00M
6-K · filed 2017-11-02
$11.00M
6-K · filed 2016-11-15
$174.00M
derived: sum of 2 quarters · filed 2017-11-02
$510.00M
6-K · filed 2017-11-02
-$510.00M
6-K · filed 2016-11-15
$273.00M
derived: sum of 4 quarters · filed 2018-02-12
2016-06-30$185.00M
6-K · filed 2017-08-03
-$185.00M
6-K · filed 2016-08-04
$521.00M
6-K · filed 2017-08-03
-$521.00M
6-K · filed 2016-08-04
$284.00M
derived: sum of 3 quarters · filed 2018-02-12
$277.00M
derived: sum of 4 quarters · filed 2018-02-12
2016-03-31$336.00M
6-K · filed 2017-05-11
-$336.00M
6-K · filed 2016-05-09
$99.00M
derived: sum of 2 quarters · filed 2018-02-12
$92.00M
derived: sum of 3 quarters · filed 2018-02-12
-$7.00M
derived: sum of 4 quarters · filed 2018-02-12
2015-12-31-$237.00M
derived: 10-K 12 month − 6-K 9 month · filed 2018-02-12
-$244.00M
derived: sum of 2 quarters · filed 2018-02-12
-$343.00M
derived: sum of 3 quarters · filed 2018-02-12
-$135.00M
10-K · filed 2018-02-12
2015-09-30-$7.00M
6-K · filed 2016-11-15
$7.00M
6-K · filed 2015-10-29
-$106.00M
derived: sum of 2 quarters · filed 2016-11-15
$102.00M
6-K · filed 2016-11-15
-$102.00M
6-K · filed 2015-10-29
$16.00M
derived: sum of 4 quarters · filed 2017-02-15
2015-06-30-$99.00M
6-K · filed 2016-08-04
$99.00M
6-K · filed 2015-07-30
$109.00M
6-K · filed 2016-08-04
-$109.00M
6-K · filed 2015-07-30
$23.00M
derived: sum of 3 quarters · filed 2017-02-15
-$133.00M
derived: sum of 4 quarters · filed 2017-02-15
2015-03-31$208.00M
6-K · filed 2016-05-09
-$208.00M
6-K · filed 2015-04-30
$122.00M
derived: sum of 2 quarters · filed 2017-02-15
-$34.00M
derived: sum of 3 quarters · filed 2017-02-15
-$39.00M
derived: sum of 4 quarters · filed 2017-02-15
2014-12-31-$86.00M
derived: 20-F 12 month − 6-K 9 month · filed 2017-02-15
-$242.00M
derived: sum of 2 quarters · filed 2017-02-15
-$247.00M
derived: sum of 3 quarters · filed 2017-02-15
-$237.00M
20-F · filed 2017-02-15
2014-09-30-$156.00M
6-K · filed 2015-10-29
-$161.00M
derived: sum of 2 quarters · filed 2015-10-29
-$151.00M
6-K · filed 2015-10-29
-$111.00M
derived: sum of 4 quarters · filed 2016-02-11
2014-06-30-$5.00M
6-K · filed 2015-07-30
$5.00M
6-K · filed 2015-07-30
$45.00M
derived: sum of 3 quarters · filed 2016-02-11
$121.00M
derived: sum of 4 quarters · filed 2016-02-11
2014-03-31$10.00M
6-K · filed 2015-04-30
$50.00M
derived: sum of 2 quarters · filed 2016-02-11
$126.00M
derived: sum of 3 quarters · filed 2016-02-11
$180.00M
derived: sum of 4 quarters · filed 2016-02-11
2013-12-31$40.00M
derived: 20-F 12 month − 6-K 9 month · filed 2016-02-11
$116.00M
derived: sum of 2 quarters · filed 2016-02-11
$170.00M
derived: sum of 3 quarters · filed 2016-02-11
$104.00M
20-F · filed 2016-02-11
2013-09-30$76.00M
6-K · filed 2014-10-30
$130.00M
derived: sum of 2 quarters · filed 2014-10-30
$64.00M
6-K · filed 2014-10-30
$139.00M
derived: sum of 4 quarters · filed 2015-02-09
2013-06-30$54.00M
6-K · filed 2014-07-31
-$12.00M
6-K · filed 2014-07-31
$63.00M
derived: sum of 3 quarters · filed 2015-02-09
$91.00M
derived: sum of 4 quarters · filed 2015-02-09
2013-03-31-$66.00M
6-K · filed 2014-05-02
$9.00M
derived: sum of 2 quarters · filed 2015-02-09
$37.00M
derived: sum of 3 quarters · filed 2015-02-09
-$71.00M
derived: sum of 4 quarters · filed 2015-02-09
2012-12-31$75.00M
derived: 20-F 12 month − 6-K 9 month · filed 2015-02-09
$103.00M
derived: sum of 2 quarters · filed 2015-02-09
-$5.00M
derived: sum of 3 quarters · filed 2015-02-09
$63.00M
20-F · filed 2015-02-09
2012-09-30$28.00M
6-K · filed 2013-10-31
-$80.00M
derived: sum of 2 quarters · filed 2013-10-31
-$12.00M
6-K · filed 2013-10-31
-$51.00M
derived: sum of 4 quarters · filed 2014-02-10
2012-06-30-$108.00M
6-K · filed 2013-08-01
-$40.00M
6-K · filed 2013-08-01
-$79.00M
derived: sum of 3 quarters · filed 2014-02-10
-$133.00M
derived: sum of 4 quarters · filed 2014-02-10
2012-03-31$68.00M
6-K · filed 2013-05-02
$29.00M
derived: sum of 2 quarters · filed 2014-02-10
-$25.00M
derived: sum of 3 quarters · filed 2014-02-10
-$3.00M
derived: sum of 4 quarters · filed 2014-02-10
2011-12-31-$39.00M
derived: 20-F 12 month − 6-K 9 month · filed 2014-02-10
-$93.00M
derived: sum of 2 quarters · filed 2014-02-10
-$71.00M
derived: sum of 3 quarters · filed 2014-02-10
-$40.00M
20-F · filed 2014-02-10
2011-09-30-$54.00M
6-K · filed 2012-11-01
-$32.00M
derived: sum of 2 quarters · filed 2012-11-01
-$1.00M
6-K · filed 2012-11-01
2011-06-30$22.00M
6-K · filed 2012-08-02
$53.00M
6-K · filed 2012-08-02
2011-03-31$31.00M
6-K · filed 2012-05-09
2010-12-31$70.00M
20-F · filed 2013-02-12